Filter Results:
(7)
Show Results For
- All HBS Web (21)
- Faculty Publications (2)
Show Results For
- All HBS Web (21)
- Faculty Publications (2)
Page 1 of 7
Results
Sort by
- March 2015 (Revised February 2022)
- Supplement
CV Ingenuity (B): Epilogue
By: Regina E. Herzlinger and Andrew Otazo
Duke Rohlen used a lea-nfunding, iconoclastic strategy for his start up for a drug eluding balloon for peripheral artery disease. His giant competitors were first movers. Did Duke obtain the funding he sought? How did his DEB fare versus that of his competitors?
The... View Details
Keywords: CV Ingenuity; CVI; Drug Eluting Balloon; DEB; Drug Eluting Stent; Angioplasty Balloon; FoxHollow; Medical Device; Medical Device Startup; Premarket Approval; PMA; Lutonix; Stellarex; LEVANT; ILLUMENATE; Clinical Trials; Peripheral Arterial Disease; PAD; Healthcare Startups; Covidien; Health Care and Treatment; Health Testing and Trials; Business Startups; Commercialization; Strategy; Health Industry; Medical Devices and Supplies Industry; United States; Europe
Herzlinger, Regina E., and Andrew Otazo. "CV Ingenuity (B): Epilogue." Harvard Business School Supplement 315-087, March 2015. (Revised February 2022.)
- March 2015 (Revised January 2024)
- Case
CV Ingenuity (A): How to Evaluate the Commercial Viability of New Health Care Technologies
By: Regina E. Herzlinger and Andrew Otazo
Duke Rohlen (HBS MBA ’01) hoped to win over a prominent venture capital investor for Series B financing of his firm CVI that was creating a drug-eluting balloon (DES) to treat peripheral arterial disease. As a second-mover, Duke felt he was more likely to acquire... View Details
Keywords: CV Ingenuity; CVI; Drug Eluting Balloon; DEB; Drug Eluting Stent; Angioplasty Balloon; FoxHollow; Medical Device; Medical Device Startup; Premarket Approval; PMA; Lutonix; Stellarex; LEVANT; ILLUMENATE; Clinical Trials; Peripheral Arterial Disease; PAD; Healthcare Startups; Covidien; Health Care and Treatment; Health Testing and Trials; Business Startups; Commercialization; Health Industry; Medical Devices and Supplies Industry; United States; Europe
Herzlinger, Regina E., and Andrew Otazo. "CV Ingenuity (A): How to Evaluate the Commercial Viability of New Health Care Technologies." Harvard Business School Case 315-045, March 2015. (Revised January 2024.)
- 01 Sep 2022
- What Do You Think?
Is It Time to Consider Lifting Tariffs on Chinese Imports?
feedback to last month’s column Does Religious Belief Affect Organizational Performance? We would like to think that religious belief does affect organizational performance. Deb Wiesner expressed this feeling in an email response to the... View Details
Keywords: Re: James L. Heskett
- 06 Jul 2009
- What Do You Think?
Are You Ready to Manage in an Irrational World?
new technology . Is (it) irrational (to) place a higher value on their current solution than they do on a future uncertain benefit(?)" What about the impact on management? Nicola Stevens concluded that "It (irrational behavior) makes suspect much of what we... View Details
Keywords: by Jim Heskett
- 02 Aug 2004
- Research & Ideas
Health Care Research and Prospects
come as a surprise to a lot of companies who are spending a lot of money and not getting a payoff for it. Q: There's been a lot of controversy around the ethics of stem cell research and cloning. Have you been keeping an eye on that? A: There's actually a major project... View Details
- 10 Sep 2013
- First Look
First Look: September 10
of metrics to describe TV programs and broadcast advertising. Co-Founder and CEO Deb Roy said: "We want to measure audience engagement, not just media consumption." But what was the value of audience engagement? How could it be... View Details
Keywords: Sean Silverthorne
- 13 Oct 2003
- Research & Ideas
Negotiating Challenges for Women Leaders
are more flexible. You're only going to be enhancing all worker commitments. You're likely to be better at retaining talent, too. There's a nice example of what organizations can do from work by Maureen Scully and Deb Myerson. They... View Details
Keywords: by Martha Lagace